Online ISSN: 1884-4111 Print ISSN: 0033-8303
Radioisotopes 69(5): 179-187 (2020)

連載講座Serial Lecture

放射性同位体の医学的利用に関する概括とα線放出核種の適用についての新たな展開An Overview of the Radioisotopes in Nuclear Medicine and Following Discussion on Promising Success of the Targeted Alpha Therapy

国立研究開発法人量子科学技術研究開発機構量子医学・医療部門放射線医学総合研究所先進核医学基盤研究部放射性核種製造グループTargetry and Target Chemistry Group, Department of Advanced Nuclear Medicine Sciences, National Institute of Radiological Sciences, National Institutes for Quantum and Radiological Science and Technology

発行日:2020年5月15日Published: May 15, 2020


This report describes an overview of the radioisotopes used in nuclear medicine. The statistic information on the frequency was acquired via an online survey provided by the Journal of Nuclear Medicine. In this decade, most frequent workhorses of radioisotope are found to be positron-emitters for PET diagnostic tests, as well as beta-emitters for therapeutic application. These results suggest that ‘theranostics’ in nuclear medicine has already been widely accepted as the mainstream of medical treatment and the evidence for the applicable way of radioactive materials. In addition, targeted alpha therapy (TAT), an emerging therapy with appropriate alpha-emitters appeared in this decade, gives the highest impact to our community. The TAT has great potential to stimulate our research activities, as well as to enhance the following clinical achievements.

Key words: targeted radionuclide therapy (TRT); targeted alpha therapy (TAT); radioisotope; nuclear medicine; emerging radionuclide; theranostics; alpha-emitter

This page was created on 2020-02-21T17:20:45.283+09:00
This page was last modified on 2020-04-27T15:13:46.000+09:00